They are termed GR modulators, are steroidal or non-steroidal in nature (Ray et al. 2007, Clark 2008, Belanoff et al. 2010, De Bosscher 2010, Gross et al. 2010), and are geared toward treating Cushing's syndrome as well as other conditions in which excess GR activity needs to be depressed without affecting PR-mediated physiological processes. Here, NR3C1 is linked to Cushing syndrome.